Science News
from research organizations

Antihypertensives associated with lower dialysis risk for patients with advanced CKD

Date:
December 16, 2013
Source:
The JAMA Network Journals
Summary:
Patients with stable hypertension and the most advanced stage of chronic kidney disease before dialysis appeared to have a lower risk for long-term dialysis or death if they were treated with the antihypertensive drugs known as angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, according to a study published.
Share:
       
FULL STORY

Patients with stable hypertension and the most advanced stage of chronic kidney disease (CKD) before dialysis appeared to have a lower risk for long-term dialysis or death if they were treated with the antihypertensive drugs known as angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs), according to a study published by JAMA Internal Medicine, a JAMA Network publication.

An ACEI or ARB is known to delay the progression of CKD in patients with and without diabetes, particularly in those patients with mild to moderate renal insufficiency. But most large clinical trials of ACEI/ARB exclude patients with the most advanced stage of CKD predialysis, perhaps out of concern that the drugs can cause renal failure and the need for dialysis, so it remains unclear whether that therapy is effective in patients with advanced CKD, according to the study background.

Researchers in Taiwan examined the association between ACEI/ARB use and the risk of long-term dialysis and death in a nationwide group of 28,497 patients in a study by Ta-Wei Hsu, M.D., of the National Yang-Ming University Hospital, and colleagues. The patients had the most advanced predialysis stage of CKD, hypertension and anemia.

During a median follow-up of seven months, 20,152 patients (70.7 percent) required long-term dialysis and 5,696 (20 percent) died before progressing to ESRD (end-stage renal disease). Study findings indicate that treatment with ACEIs/ARBs in patients with stable hypertension and advanced CKD was associated with a lower risk for long-term dialysis or death by 6 percent.

"In conclusion, our findings expand the existing knowledge in the field and provide clinicians with new information," the authors conclude.


Story Source:

The above post is reprinted from materials provided by The JAMA Network Journals. Note: Materials may be edited for content and length.


Journal Reference:

  1. Ta-Wei Hsu, Jia-Sin Liu, Szu-Chun Hung, Ko-Lin Kuo, Yu-Kang Chang, Yu-Chi Chen, Chih-Cheng Hsu, Der-Cherng Tarng. Renoprotective Effect of Renin-Angiotensin-Aldosterone System Blockade in Patients With Predialysis Advanced Chronic Kidney Disease, Hypertension, and Anemia. JAMA Internal Medicine, 2013; DOI: 10.1001/jamainternmed.2013.12700

Cite This Page:

The JAMA Network Journals. "Antihypertensives associated with lower dialysis risk for patients with advanced CKD." ScienceDaily. ScienceDaily, 16 December 2013. <www.sciencedaily.com/releases/2013/12/131216183849.htm>.
The JAMA Network Journals. (2013, December 16). Antihypertensives associated with lower dialysis risk for patients with advanced CKD. ScienceDaily. Retrieved July 1, 2015 from www.sciencedaily.com/releases/2013/12/131216183849.htm
The JAMA Network Journals. "Antihypertensives associated with lower dialysis risk for patients with advanced CKD." ScienceDaily. www.sciencedaily.com/releases/2013/12/131216183849.htm (accessed July 1, 2015).

Share This Page: